About Dr Mischel Neill

Dr Mischel Neill is a Urological Surgeon in private practice in Auckland, New Zealand. He also has a public consultant appointment at North Shore Hospital and provides acute on-call care at Auckland City Hospital.

Misch underwent medical training at the University of Auckland, graduating in 1995. His subsequent postgraduate experience has largely been in New Zealand, with short stints in South Africa, Western Samoa and The United Kingdom. He became a Fellow of the Royal Australasian College of Surgeons in 2005.

Misch has developed particular interests in urologic oncology (cancer management) and minimally invasive (keyhole) surgery, with extensive overseas postgraduate training.

He spent two years at the University of Toronto, based at Toronto General, Princess Margaret and Sunnybrooke Hospitals. This was under the supervision of programme directors Professor Laurence Klotz and Professor Michael Jewett, recognized as being amongst North America’s foremost urologists. The programme was designed and accredited by The Society of Urologic Oncologists and provided extensive exposure to the diagnosis and management of all aspects of kidney, bladder, prostate, penile and testicular cancer.

Following this he relocated to England for a year to focus exclusively on advanced laparoscopic training with the United Kingdom’s most well-known and respected laparoscopic urologist, Mr Christopher Eden.

Since returning home he has undertaken further education in robotic surgery. This was based firstly in the San Francisco Bay region, USA.  He underwent training at the global centre for Intuitive in Sunnyvale near Palo Alto, where the Da Vinci robot was designed and developed, followed by time spent at Stanford University Hospital.  He later visited MD Anderson Cancer Centre in Houston, Texas for further robotic exposure.

Prior to COVID induced public lockdowns he was able to undertake a working sabbatical, visiting a number of world leading cancer and laparoscopic centres in the UK, Europe and India.

Misch has always had an interest in medical research. He has written book chapters, presented at international urological meetings and published widely in many urological journals, serving on the editorial board or as a reviewer for several of them.

In addition, Misch is active in the public hospital service as well. After expanding laparoscopic urology and introducing laparoscopic prostatectomy to the Waitemata region he has more recently been involved in the initiation of the Robotic Surgery Pilot Programme. This programme is based at North Shore Hospital, with the eventual aims of  establishing the feasibility of further robotic centres throughout the country and training future robotic surgeons. In this capacity he performed the first robotic procedure in New Zealand’s public sector.

He has been the Urology Registrar Training Supervisor for the Waitemata region for many years.

Misch lives with his wife and two children who keep him in line.

 

Career history

  • Bachelor of Human Biology (BHB)
    The University of Auckland, New Zealand, May 1992

    Bachelor of Medicine and Surgery (MBChB) (A Pass)
    The University of Auckland, New Zealand May 1995

    Fellowship of the Royal Australasian College of Surgeons
    Royal Australasian College of Surgeons, New Zealand & Australia, October 2004

  • House Surgeon

    Auckland Regional Hospitals — 1994 to 1995
    Auckland, New Zealand

    Hastings & Napier Hospitals — 1994 to 1995
    Hastings & Napier, Hawkes Bay, New Zealand

    Senior House Officer

    Torbay District General Hospital — 1997 to 1998
    Torquay, Devon, UK

    Auckland Regional Hospitals — 1998 to 1999
    Auckland, New Zealand

    Basic Surgical Training Registrar

    Waikato Hospital — 1999 to 2000
    Hamilton, New Zealand

    Auckland Regional Hospitals — 2000 to 2001
    Auckland, New Zealand

    Advanced Urology Training Registrar

    Auckland Regional Hospitals - Auckland, New Zealand 2001 - 2002

    Waikato Hospital - Hamilton, New Zealand 2002 - 2003

    Tauranga Hospital - Bay of Plenty, New Zealand 2003 - 2004

    Medical Officer of Special Scale in Urology

    Auckland Regional Hospitals - Auckland, New Zealand 2005 (5/12)

    Uro-Oncology Fellow, Society of Urologic Oncology

    Princess Margaret Hospital

    Toronto General Hospital

    Sunnybrook Hospital

    Toronto, Ontario, Canada 2005 – 2007

    Prof Laurence Klotz
    Prof Michael Jewett

    Medical Officer of Special Scale in Urology

    North Shore Hospital — 2007
    Auckland, New Zealand

    Laparoscopic Urology Fellow

    Royal Surrey County Hospital

    North Hampshire Hospital

    The Hampshire Clinic

    Guildford and Basingstoke, Surrey and Hampshire, UK 2007 – 2008

    Mr Christopher Eden

    Consultant Urologist

    North Shore and Waitakere Hospitals
    Auckland, New Zealand from Oct 13, 2008

    Auckland City Hospital (acute services)
    Auckland, New Zealand from Oct 13, 2008

  • Anterior Urethroplasty : Should you just go with the flow?

    M. Neill, R. Chambers; 2002
    Presented at USA – NZ sectional meeting 2002, AGM 2003
    Abstract published in Australia and New Zealand Journal of Surgery 2003; 73, A337

    Benign Prostatic Hyperplasia.

    M. Neill, P. Gilling; 2004
    Published in Shah J, Ed, Fast Facts - Urology Highlights 2004-5,
    2005 Edition, Chapter 2. Health Press Limited, 2005: 18-30

    The prevalence of herbal remedy usage in the urological outpatient clinic.

    M.G. Neill, M.A. Holmes, W. Wright, G. Lockwood, P. Bary; 2003
    Presented at AUA annual meeting, 2007
    Abstract published in Journal of Urology 2007

    Randomized trial comparing Holmium laser enucleation of the prostate with plasmakinetic enucleation of the prostate for the treatment of benign prostatic hypertrophy.

    M. Neill, P. Gilling, K. Kennet, C. Frampton, A. Westenberg, M. Fraundorfer, Wilson LC; 2004
    Published in Urology 2007; 68(5): 1020-4

    The impact of prostate size on biopsy outcome at low PSA levels.

    M. Neill, N. Fleshner, G. Andriole; 2005
    Published in Urology Times 2005; 33(14): 30-1

    Predictors of transfusion requirement in open radical prostatectomy.

    M. Neill, S. McCluskey, G. Lockwood, N. Fleshner; 2006
    Presented at the Canadian Urological Association Annual General Meeting; Halifax 2006
    Abstract published in Canadian Journal of Urology 2006

    The continuing importance of transrectal ultrasound identification of prostatic lesions.

    A. Toi, M. Neill, G. Lockwood, J. Sweet, L. Tammsalu, N. Fleshner; 2006
    Published in Journal of Urology 2007; 177(2): 526-20

    An update in chemoprevention strategies in prostate cancer for 2006.

    M.G.Neill, N.E. Fleshner; 2005
    Published in Current Opinion in Urology 2006; 16(3): 132-7

    Preoperative evaluation of the hostile pelvis with CT pelvimetry prior to radical prostatectomy.

    M. Neill, G. Lockwood, S. McCluskey, N. Fleshner; 2006
    Published in BJU International 2007; 99(3): 534-8

    The presentation of transitional cell carcinoma of the prostate and use of transrectal ultrasound guided biopsy in it’s detection.

    M.G. Neill, J. Azuero, G.A. Lockwood, M.A.S. Jewett
    Poster presentation at European Association of Urologists Annual Meeting
    Milan, 2008
    Abstract published in European Urology 2008

    The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.

    M.G. Neill, L.W. Le, G Studer, M McLean, G Pond, J Crook; 2006
    Published in Brachytherapy 2007; 6(3): 173-9

    Systematic lateral prostatic biopsy: are the benefits worth the costs?

    A. Toi, M.G. Neill, G.A. Lockwood, A. Evans, L.Tammsalu, N.E. Fleshner; 2006.
    Published in Journal of Urology 2008; 179(4): 1321-6

    Feasibility of a monopolar, loosely wound helical coil for interstitial radiofrequency thermal therapy: Numerical and In vivo studies.

    C. McCann, M.G. Neill, M.A.S. Jewett, J.R. Kachura, M.R.Gertner, A.Worthington, A.Tobar, A.M.
    Herzenberg, M.Boesen, M.D. Sherar; 2006
    Presented doctoral thesis

    Management of low stage seminoma.

    M.G. Neill, P. Warde, N.E. Fleshner; 2006
    Published in Urological Clinics North America 2007; 34(2): 127-36

    The once and future role of cytoreductive nephrectomy.

    M.G. Neill, M.A.S. Jewett; 2006
    Published in Urologic Oncology 2008;26(4): 346-52

    Case Report: Consolidative metastectomy for renal cell carcinoma following partial response to multitarget tyrosine kinase inhibitor therapy.

    M.G.Neill, A.C. Wei, M.A.S. Jewett; 2006
    Published in Urology 2007; 70(1): 178e9-11

    Accuracy of endoscopic staging and grading of bladder tumours with flexible and digital cystoscopes.

    M.A.S. Jewett, K Hersey, E Grober, M.G. Neill, R Lopez, A Sathiananthan, G Lockwood, A Evans, E Seto, N.E. Fleshner,; 2006
    Presented at the Canadian Urological Association Annual General Meeting;
    Quebec City, 2007
    Abstract published in Canadian Journal of Urology 2007

    Management of the complications of hormonal treatment for prostate cancer.

    M.G. Neill, N.E. Fleshner; 2007
    Commissioned as Chapter 9 of the 4th edition of “Complications of Urologic Surgery: Prevention and Diagnosis”
    Published 2009

    Strategies for the preservation of prostate health.

    M.G. Neill, S Appu, A.R. Zlotta.
    Published in Drugs Today (Barc). 2009 Jan;45(1):63-80

    Tamsulosin Oral Controlled Absorption System (OCAS) in the treatment of Benign Prostatic Hypertrophy.

    M.G. Neill, R. Shohani, A.R. Zlotta.
    Published in Therapeutics and clinical risk management 2008; 4(1): 11-8.

    Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localized prostate cancer.

    R.K Nam, L. Sugar, W Yang, S. Srivastava, L.H. Klotz, L-Y. Yang, A. Stanimirovic, E. Encioiu, M.G. Neill, D.A. Loblaw, J. Trachtenberg, S.A. Narod, A. Seth.
    Published in British Journal of Cancer 2007; 97(12): 1690-5.

    Curtain dissection of the lateral prostatic fascia and potency following laparoscopic radical prostatectomy – a veil of mystery.

    C. Chabert, A.D. Merrilees, M.G. Neill, C. Eden.
    Published in BJU Int 2008; 101(10): 1285-8

    Letter : Laparoscopic radical prostatectomy in the UK : defining and overcoming the obstacles.

    C. Chabert, M.G. Neill, C. Eden.
    Published in BJU Int 2008;101(3): 393

    Letter : Seminal vesicle-sparing radical prostatectomy improves early functional results in patients with low risk prostate cancer.

    C. Chabert, M.G. Neill, C. Eden.
    Published in BJU Int 2008;101(3): 394

    Laparoscopic radical prostatectomy: the impact of training on service provision.

    M.G Neill, C. Chabert, A.D. Merrilees, C. Eden
    Published in BJU Int 2009; 103(9):1231-4

    Laparoscopic radical prostatectomy for cT3 prostate cancer

    M.W. Louie-Johnsun, M.G Neill, C. Chabert, C. Eden
    Abstract published in European Urology 2008

    Does intrafascial dissection during nerve-sparing laparoscopic radical prostatectomy compromise cancer control?

    M.G Neill, C. Chabert, M.W. Louie-Johnsun, C. Eden
    Abstract published in European Urology 2008

    The UK’s first 1,000 cases of laparoscopic radical prostatectomy: evidence of multiple learning curves.

    C. Eden, M.G Neill, M.W. Louie-Johnsun
    Published in BJU Int. 2009; 103(9):1224-30

    Final outcomes of patients with low-risk prostate cancer suitable for active surveillance but treated surgically.

    M.W. Louie-Johnsun, M Neill, K Treurnicht, M Jarmulowicz, C Eden
    Published in BJU Int. 2009 May 7. [Epub ahead of print]

    The learning curve for positive margin rates following laparoscopic radical prostatectomy.

    C. Eden, M.W. Louie-Johnsun, M. Neill
    Abstract published in Clinical Oncology 2009;21(1):69

    Clinical Trials Investigator

    A phase III parallel group, randomised, open label, multi-centre clinical trial of zolendronic acid (Zometa) in males receiving androgen deprivation therapy for advanced prostate cancer.

    Novartis

    A randomised multi-centre study of Denosumab compared with Zolendronic acid in the treatment of bone metastases in hormone refractory prostate cancer.

    Amgen

    A prospective study of a novel urine diagnostic test for the detection of urinary tract transitional cell carcinoma.

    Pacific Edge Biotech

    A double-blind placebo-controlled study to evaluate new or worsening lens opacification in subjects with non-metastatic prostate cancer receiving Denosumab for bone loss due to androgen deprivation therapy.

    Amgen

    A randomised double blind multi-centre trial comparing Orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with chemotherapy naieve metastatic castrate resistant prostate cancer.

    Millenium

  • Australia and New Zealand Urogenital and Prostate Cancer Trials Group

    Urological Society of Australia and New Zealand member

    Royal Australasian College of Surgeons member

    European Association of Urologists member

    American Urological Association member

    New Zealand Genito-urinary Cancer Special Interest Group member